secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001104659-24-008839
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode regains Nasdaq equity compliance; still faces bid price rule non-compliance with May 6 deadline
--------------------------------------------------------------------------------

- Nasdaq determined TransCode met minimum $2.5M stockholders' equity requirement for continued listing.
- Company placed on mandatory panel monitor through January 26, 2025, subject to delisting if non-compliant again.
- Separately, TransCode remains non-compliant with minimum $1.00 bid price rule; must cure by May 6, 2024.
- Failure to meet bid price rule could lead to additional 180-day compliance period if other listing standards are met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924008839/0001104659-24-008839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924008839/tm244740d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-008839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer